NEW YORK (360Dx) – Guardant Health said that its Guardant360 liquid biopsy assay has received expedited access pathway designation from the US Food and Drug Administration. The designation will allow the company to work with the FDA to finalize its data-development plan as it prepares a regulatory submission later this year, Guardant Health said. The liquid biopsy test was developed so that oncologists can select the most appropriate treatment for their patients, eliminating the need for an invasive tissue biopsy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.